ROCHE-M77001

Study Sponsor: Roche

Study Title

A Multicenter, Randomized Comparative Study on the Efficacy and Safety of Herceptin (Trastuzumab) Plus Docetaxel (Taxotere) Versus Docetaxel Alone as First Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer

Medicine or Vaccine (generic name)

trastuzumab

Sponsor Identification Number

M77001

Trial Registry Identification Number(#'s)

Medical Condition

HER2-positive metastatic breast cancer

Phase

Phase 2

Link to study details on the Roche Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Additional information about the data and documents available for this study

Date Added to this Site

July 2015